Black Diamond Therapeutics (BDTX)
(Delayed Data from NSDQ)
$5.30 USD
-0.40 (-7.02%)
Updated Apr 18, 2024 04:00 PM ET
2-Buy of 5 2
D Value B Growth B Momentum C VGM
Income Statements
Fiscal Year end for Black Diamond Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 86 | 93 | 127 | 70 | 29 |
Income After Depreciation & Amortization | -86 | -93 | -127 | -70 | -29 |
Non-Operating Income | 4 | 4 | 1 | 2 | -6 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -82 | -89 | -126 | -67 | -35 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | -2 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -82 | -91 | -126 | -67 | -35 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -82 | -91 | -126 | -67 | -35 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -86 | -92 | -127 | -70 | -29 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -86 | -93 | -127 | -70 | -29 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 43.96 | 36.33 | 36.19 | 32.91 | 2.08 |
Diluted EPS Before Non-Recurring Items | -1.88 | -2.52 | -3.47 | -2.05 | -16.99 |
Diluted Net EPS (GAAP) | -1.88 | -2.52 | -3.47 | -2.05 | -16.99 |
Fiscal Year end for Black Diamond Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 20.86 | 24.01 | 20.03 | 21.56 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -20.86 | -24.01 | -20.03 | -21.56 |
Non-Operating Income | NA | 1.45 | 1.01 | 0.88 | 0.69 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -19.41 | -23.01 | -19.15 | -20.88 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -19.41 | -23.01 | -19.15 | -20.88 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -19.41 | -23.01 | -19.15 | -20.88 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 51.64 | 50.94 | 36.52 | 36.48 |
Diluted EPS Before Non-Recurring Items | NA | -0.34 | -0.45 | -0.52 | -0.57 |
Diluted Net EPS (GAAP) | NA | -0.34 | -0.45 | -0.52 | -0.57 |